Cellares is revolutionizing cell therapy manufacturing. Cellares is developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit.

Cellares

Victor Tong

Justin Butler

Fabian Gerlinghaus

Cellares develops the Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit. The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope. Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale.  Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively, and at the scale they need. The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates, and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.

Biotechnology Companies

Medical Organizations

Health Care Companies

Software Companies

Omar Kurdi

Alex Pesch

Eclipse Ventures

8 | partners

EcoR1 Capital

Decheng Capital

Skyviews Life Science

Koch Disruptive Technologies

Willett Advisors

Financial services company based in New York City, New York

Bristol-Myers Squibb

DFJ Growth

Venture capital firm specializing in digital and life science

South San Francisco

City in San Mateo County, California, United States

United States of America

Country primarily located in North America

San Francisco Bay Area

Metropolitan area in California, United States

California

San Mateo County

San Francisco

Consolidated city and county in California, United States

Research and Development in Biotechnology (except Nanobiotechnology)

Research and Development in the Physical, Engineering, and Life Sciences

Scientific Research and Development Services

Professional, Scientific, and Technical Services

Software Publishers

Publishing Industries

Information

Nursing and Residential Care Facilities

Health Care and Social Assistance

Publishing Industries (except Internet)

Health Care and Social Assistance, Health

Fred Hutch

Cancer research institute in Seattle, Washington, United States

Lyell Immunopharma

Company in South San Francisco, United States

Cabaletta Bio

Commercial Physical And Biological Research

Research, Development, And Testing Services

Engineering, Accounting, Research, Management, And Related Services

Prepackaged Software

Computer Programming, Data Processing, And Other Computer Related

Business Services

Offices And Clinics Of Health Practitioners, Not Elsewhere Classified

Offices And Clinics Of Other Health Practitioners

Health Services

Linkedin Sign-in

MediaElement.js

Smart Slider 3

Google Font API

jQuery Migrate

Google Remarketing Tag

core-js

web-vitals

Cloudflare Browser Insights

Google Analytics

jQuery

MySQL

Divi

Google Tag Manager

WordPress

Kinsta

Yoast SEO

Elasticsearch

Gene therapy

Azure Active Directory

TrackWise

Linux

Blazor

Biochemistry

Azure DevOps Server

SendGrid

Microsoft Windows

Fluidics

Benchling

TypeScript

Microsoft Azure

ASP.NET Core

Biotechnology

Cellares Funding & Investors

Total Amount Raised: $355,000,000

Cellares Funding Rounds

Series C Investors

Series B Investors

Series A Investors

💸 Investors

📚 Popular Blog Posts